Drug intelligence / Profile preview

Chaihu Shengjiang Formula

Development stage: Preclinical
Lead developer: Southwest Medical University
Administration: Oral

Overview

Chaihu Shengjiang Formula is a traditional Chinese medicine formula, administered as a granule, currently under clinical investigation for the treatment of refractory chronic cough. Specifically, it targets cases identified as liver-fire invading lung syndrome, a diagnosis within traditional Chinese medicine theory. The formula is based on the concept of ''persistent cough, suffering from three Jiao''.

Other names: Chaihu ascending and descending prescriptionChaihu Shengjiang Granule

Beyond the preview

Go deeper on Chaihu Shengjiang Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chaihu Shengjiang Formula.

Explore the full profile